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Currently. for the patient with type I diabetes, a definitive treatment without resorting to the 
use of exogenous insulin can be achieved only with pancreas or islet cell transplantation. These 
means of restoring ~-cell mass can completely maintain essentially normal long-term glucose 
homeostasis, although the need for powerful immunosuppressive regimens limits their 
application to only a subgroup of adult patients. Apart from the shortage of donors that has 
limited all kinds of transplantation. however, the widespread use of ~-cell replacement has been 
precluded until recently by the drawbacks associated with both organ and islet cell 
transplantation. Although the study of recurrence of diabetes has generated attention, the 
fundamental obstacle to pancreas and islet transplantation has been, and remains, the 
alloimmune response. With a better elucidation of the mechanisms of alloengraftment achieved 
during the last 3 years, the stage has been set for further advances. 
'Key words: type I diabetes; autoimmunity; allorejection; immunosuppression; tolerance. 
The different aetiological types of diabetes mellitus are designated type I. type 2 and 
other specific types. I Type I diabetes is characterized by ~-cell destruction and the 
requirement of insulin treatment for survival. Type 2 diabetes is a metabolic disorder 
due to an interplay between dysfunctional insulin production and impaired periphor 
"'Address for correspondence: Children's Hospital of Pittsburgh. Rangos Research Center, 3460 Fifth Avenue. 
Pittsburgh, PA 15213. USA 
1521-6918102/$ - see front matter- (S: 2002 Elsevier- SCience Ltd. All rights reserved Ltd. 
~;:KIK~ ~ .. ~ :- - ,... :. 
, 
.JI'(,j)( ,.."'<1'11 ~~K ~> I~/ ~I 
458 R. Bottino et al 
response. The other forms of impaired glucose homeostasis can be due to different 
genetic defects. destruction of the exocrine pancreas or malfunction of other endocrine 
organs. 1 
In 1997 the number of people affected by diabetes mellitus was approximately 130 
million worldwide. with an overwhelming preponderance of type 2 (> 90%). For 
mUltiple reasons. it is estimated that the total will reach 220 million by the year 2010.2 
The rise is not expected to be homogeneously distributed. For example. changes in 
lifestyle in 'recently modernized' parts of the world (e.g. Asian and African countl-ies) 
will probably result in disproportionately higher increases in diabetes. In contrast. the 
fraction of type I diabetes is expected to increase over time in developed countries 
where longer survival after diagnosis results from greater availability of sophisticated 
care. Relative to the Caucasian popUlation, the incidence of. and the genetic 
susceptibility to. diabetes and its complications, selectively target ethnic groups such 
as African-Americans. Hispanic-Americans and Native Americans.3- s 
Despite improvements in care, the life expectancy of victims of diabetes is at least 
10 years shorter in the United States than that of the rest of the population.3 
Cardiovascular disease, end-stage renal disease and diabetic retinopathy are the major 
morbidity factors in diabetic people.s-7 One-third of all type I diabetic individuals have 
one or more lethal or life-ruining complications that are directly attributable to the 
underlying diabetes. 
The prevention of these and other complications has been improved by technologies 
that allow the accurate monitoring of blood sugar and/or more flexible administration 
of appropriate quantities of insulin (i.e. intensified therapy). The Diabetes Control and 
Complicatiqn Trial (DCCT) has examined the impact of glycaemic control on the early 
occurrence of microvascular. neuropathic and macrovascular complications8 in type I 
diabetic patients. These studies demonstrated that intensive insulin therapy with tight 
glycaemic control could reduce but not completely eliminate the risk for development 
of some of the most devastating complications. 
For the patient with type I diabetes. definitive treatment without resorting to the 
use of exogenous insulin can be achieved presently only with pancreas or islet cell 
transplantation. These means of restoring ~-cell mass can completely maintain 
essentially normal long-term glucose homeostasis. Apart from the shortage of donors 
that has limited all kinds of transplantation. however. the widespread use of pancreas 
transplantation has been precluded until recently by the imperfections of both organ 
and islet cell transplantation. 
PANCREAS TR'ANSPLANTATION 
The unresolved problems of pancreas transplantation that were identified from the 
beginning were both technical and immunological. The immunological category has 
been the most important. the least understood. and therefore, the most daunting. 
Rejection has not been the only immune barrier because even I"ecurrence of 
autoimmune diabetes occur/"eo in recipients of panCJ"eatic grafts 9 The fundamental 
':Jbstacie co pancreas transplantation has been. and I"emains, the allolmmune I"esponse 
"Tloullted against genetically non-identlcai donor tISsue. The quality of immunosup-
pression has dictated which of the various operative procedures was :tdopted. 
Moreover", the Illorbidity and mortality inherent III chmllic ImmunosuppreSSion 
~lntlnues even coday :0 ,nfluence che selection of l-eClplents. 
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Immunosuppression 
"'ltC! the. definitive demonstration by Gibson and Medawar' that l'eJectlon IS an 
Immune I-eactlon. ulal and error efforts began in the eal-Iy 1950s to weaken the alloaraft 
, . b 
! DDD~DfIDD?nD I'espans" WitI' "Tad,atlon and dl'ugs.'! As expectec;, tlife ilst of compiicatlons 
from the: !-c<;ultlng loss or immune surveillance was a long one that could be diVided In 
two calegones: susceptibility to Infections and the development of de novo malignancies, 
ii! Jdditlorl, every potent Immunosuppressant has Its speCIfic tOXicity profile, Of the 
dozens of drugs that have been tested clinically, only three have been widely used fOI· 
continuous baselme therapy azathioprine l2 , cyclosponne 13 Jnd tacrollmus." 
Dose ranges are available for these immunosuppressants, but for each, and fOI- more 
recently Introduced ones (e.g, sirolimus ls and mycophenolate mofetil, MMF lb), the 
appmpriate dose must be established by trial and error for evel-y transplant recipient. 
The dose ceilings are imposed acutely by drug toxicity, and the dose floors are 
revealed by breakthrough rejection. The complex limiting side-effects of the 
calcineurin inhibitors (cyclosporine and tacrolimus) are of specific interest here, 
since both cyclosporine and tacrolimus are diabetogenic, nephrotoxic and neurotoxic. 
Such qualities are not seen with the other T-cell-directed agent, sirolimus, which has 
its own distinctive panoply of dose-limiting side-effects. IS 
When given after transplantation, none of the foregoing drugs can reliably prevent 
post-transplant rejection when used alone. However, it was learned in 1962-63 that 
organ rejection could readily be reversed by adding large doses of prednisone to 
primary azathioprine treatment, and that the subsequent dose requirements of both 
azathioprine and prednisone (the 'double-drug cocktail') frequently declined. '7 
In 1966, a short course of anti lymphoid globulin (ALG) was added to azathioprine and 
prednisone (the 'triple-drug cocktail'), with a substantial reduction in maintenance 
steroid doses. IS After validating the efficacy of this 'triple-drug cocktail' in kidney 
recipients, the first I-year survival of pancreas recipients was accomplished in June 
1969. 19 The overwhelming mortality with these procedures restricted expansion of 
organ transplantation for another dozen years, Then, as the more potent cyclosporine 
and tacrolimus became available, the incidence of acute rejection as well as prednisone-
dependence declined, with an increase in survival of all kinds of organ grafts in three 
distinct leaps over a 4O-year period. Thus, the modern history of organ transplantation 
can be divided into successives eras: (I) azathioprine, (2) cyclosporine and (3) tacrolimus. 
During the last decade, pancreas transplantation attained the level of a relatively 
reliable clinical service, and general agreement was finally reached about a standardized 
operation. With the definitive elucidation of the mechanisms of alloengraftment du ring 
the last 3 years, the stage has been set for further advances in what may be an era 4. 
Unlike eras 1-3, the impending era 4 may not depend on better immunosuppressants 
per se, but rather on better timing and more judicious dosing of agents that are already 
available. 
The surgical operations 
The azathioprine era 
After surgical technical problems were worked out in the canine model (summarized 
in ref. 20), Kelly and lillehei performed the first human operation at the University of 
Minnesota l9 on December 17, 1966. Under azathioprine-prednisone immunosuppres-
sion, the whole cadaveric pancreas was transplanted to the left iliac fossa of a uraemic 
recipient after removing the duodenum and ligating the pancreatic duct. A kidney 
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from the same donor was placed in the right iliac fossa. The recipient immediately 
became insulin-independent. but died at 2 months from a combination of rejection and 
sepsis. By 1973. Lillehei and Kelly had implanted 13 more whole human pancreas 
grafts. 21 Pancreatic secretions of the allografts were either exteriorized (cutaneous 
graft duodenostomy) or were directed via the graft duodenum into the host jejunum. 
using a Roux-en Y technique. The only recipient (the 6th) in this pioneer series of 14 
cases to achieve long-lasting insulin independence died shortly after reaching the I-year 
milestone with a functioning pancreas after losing the kidney graft and returning to 
dialysis. The 13 other pancreas graft losses resulted from technical complications. 
including vascular thrombosis. death with a functioning graft. and most commonly, 
lethal complications associated with exocrine pancreatic drainage. 
With the premise that the Achilles heel of the operation was exocrine drainage, 
new strategies emerged to avoid entry into the host bowel for this purpose, to 
eliminate the donor duodenum from the graft, and to prevent or reduce the volume of 
the graft secretions. In 1973, Gliedman et al 22 reported excision of the graft duodenum 
and the adjacent pancreatic head with anastomosis of the segmental pancreatic duct to 
the recipient ureter. For the next dozen years distal pancreatic segments were used 
almost exclusively for transplantation. 
The cyc/osporine era 
With the more potent cyclosporine-based immunosuppression the reasons for 
abandonment of whole-pancreas transplantation were re-examined. The conclusion 
from this analysis was that transplantation of the whole pancreas (Figure I) was the 
best procedure, provided that the allograft exocrine secretions were drained into the 
host jejunum. In a crucial modification of the original Lillehei procedure. a 'bubble' of 
duodenum into which the ampulla of Vater emptied was retained with the allograft for 
anastomosis to the side of the host jejunum (Figure 2). 
Two years later, the Iowa and Wisconsin teams advocated anastomosis of the bubble 
to the anterolateral wall of the host bladder rather than the bowel 23.24 (Figure 3). With 
diversion of exocrine secretions into the bladder, serial measurement of urine amylase 
concentration became an accepted means of immune surveillance (i.e. a drop in amylase 
signalled rejection). However, digestion of the urethra by activated pancreatic enzymes, 
less serious but highly symptomatic damage to the lower urinary tract. uncorrectable 
metabolic acidosis..J::aused by the continuous loss of bicarbonate. and a myriad of other 
problems necessitating conversion to enteric drainage have diminished enthusiasm for 
bladder d rainage.25 
The tauolimus era 
The superior control of rejection with minimal dependence on prednisone using 
tacrolimus-based immunosuppression (era 3) has further eroded the arguments for 
exocrine diverSion to the bladder: I.e. the value of urinary amylase monltol-ing and of 
avoidance of an entenc anastomosis. Moreover. it has !:leen pOSSible in simplified 
tacr-oiimus-based ;-egimens to eliminate the perioperative induction therapy 'lVith .A,LC 
or [he cnonoclonai antibody. OKT3. that had become a standard component ot 
immunosuopression aunng era 2. 
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Figure I. Whole pancreas allotransplantation with exocrine secretion drainage directly into the host 
jejunum. 
Metabolic considerations 
Portal versus systemic insulin release 
The venous effluent from a pancreas allograft can be directed by vascular anastomosis 
into the systemic venous system or into the portal venous bed from where it passes 
through the liver under normal physiological conditions. Because insulin has important 
liver-supporting (hepatotrophic) properties26 and also because the liver is the primary 
site of glucose homeostasis, an argument for portal drainage is readily apparent. In 
practice, however, this has not been an important issue, at least so far. Recipients of 
portally drained pancreas allografts usually have lower circulating insulin levels than 
those with the systemic drainage27 but no clear difference in metabolic or clinical 
outcome.28 
Correction of metabolic deficits 
Successful pancreas transplantation results in independence from exogenous insulin, 
normal blood glucose concentration, normal or near-normal HbA I c, and prompt 
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Figure 2. Pancreatico-duodenal allotransplantation with exocrine secretion drainage into the host jejunum. 
correction of ketoacidosis. The response to oral and intravenous glucose challenge and 
to secretagogues such as arginine are re-established.29 Because of improved glucagon 
and epinephrine responses, glucose-counter-regulation after hypoglycaemia is also 
restored.30.31 This has a profound impact on the quality of life since after succp.ssful 
transplantation hypoglycaemic unawareness is unlikely to occur.32 The majority of 
subjects undergoing successful transplantation consider management of the immuno-
suppressive therapy preferable to insulin injections or other metabolic complications of 
the diseaseD 
AmelioratIon of diabetes-assoclOted morbidity 
Numerous studies have shown that a successful pancreas transplant can slow micro-
'/a5cular complications. inciuding nephropathy. retinopathy and neuropathy 34-37 
DisapPOintingly. however. clear evidence has not emerged showing that pancreas 
transplantation can I-everse pre-existing lesions or completely prevent the progression 
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Figure 3. Pancreatico-duodenal allotransplantation with exocrine secretion drainage into the host bladder. 
of new ones that are diabetes-related. This could be the result of factors that are 
independent of glycaemic control. Such questions about the full nature of the disease are 
being investigated in detail, including in long-term epidemiological studies of diabetic 
versus non-diabetic populations. 
The worldwide experience 
More than 15 000 pancreas transplants have been reported to the International 
Pancreas Transplantation Registry (IPTR).38 The actual number of cases is undoubtedly 
higher because not all centres report to this registry. The transplants contributed year 
by year from 1978 to 2000 are shown in Figure 4. More than 80% of the allografts were 
co-transplanted with a kidney. but there have been more solitary pancreases in recent 
years. Patient survival reported by IPTR at I year is > 90% with simultaneous kidney-
pancreas. pancreas after kidney and pancreas alone transplantation. However, graft 
survival (insulin-free status) has been lower with solitary pancreas (71%) than with 
simultaneous kidney-pancreas transplantation (84%). Although no survival difference 
was reported with bladder versus enteric drainage of exocrine secretion, there has 
been increasing use of enteric drainage. 
While such registry data are valuable. a better understanding of how pancreas 
transplantation evolved into a genuine clinical service is obtained from detailed reports 
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Figure 4. Contemporaneous host-versus-graft (HVG) and graft-versus-host (GVH) responses following organ 
transplantation. Reproduced from Starzl TE and Zinkernagel RM (200 I. Nature Reviews in Immunology I: 
233-239) with permission. 
from large experienced centres.25.39-45 At present, only a half dozen surviving recipients 
are known to have borne functioning pancreas allografts that were transplanted before 
1985 and none before 1976.46 Early deaths and graft losses from technical complications. 
infections and rejection reached an acceptably low level only since 1995, due largely to 
the widespread acceptance of tacrolimus in that year. However. late deaths continue 
from cardiac. infectious and peripheral vascular disease, and from de novo malignancies. 
Most of these complications can be traced to, or are aggravated by, the need for chronic 
immunosuppression. As described below. it may be pOSSible to rectify this problem at 
least partly. 
Mechanisms of engraftment 
In the different eras, the successful reversal of rejection was followed by a decline in 
anti donor graft reactivity that was reflected by a reduced need for immunosuppres-
sion, and in some cases by eventual or complete independence from maintenance 
therapy.47-49 Even when rejection is not clinically evident, the need for immunosup-
pression declines. The implication was that an allograft transplanted under non-speCific 
immunosuppression could induce variable degrees of antigen-specific non-reactivity 
(tolerance).50 
In each era, however, a policy drift ensued as soon as it was recognized that some of 
the rejections developing under monotherapy were intractable. The management 
change consisted oT instituting prophylactic high-dose steroid therapy from the time of 
transplantation to all recipients. As anti lymphoid and other agents were added 
pre-emptively in increasingly complex cocktails, the unchallenged tacit assumption was 
that the efficacy of the immunosuppressive regimens could be assessed primarily by 
t:he frequency with which acute rejection could be prevented. In addition. It was 
assumed that redUCing the incidence of early rejection to near zero would be 
"ewarded by 3. commensurate decline in chronic rejection. Instead. chronic relection 
has become the greatest unresolved problem in the transplantation of all organs. With 
the possible exception of the liver. 
Relinquishing the use of high-dose immunosuppression was difficult to defend. 
largely fJecause r:he mechanisms of alloengraftment were enigmatic. The first I'eal clue 
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to thesE: mechanisms was the discovery in 1992 that bone-marrow-derlved Da5Senger 
fb:rD··K·~·~·ite= wnler, an: normill constituents of all o I-gallS , mlgl-ateu all:er tI-ansplantatlon 
::c widespread locations In the recipient and could be round penpher;}lly In small 
numbers. yeal-s 01- decades laTel-sl -53 With only this much InformaTion, It was deduced 
mac tile early evellts after transplantation are dominated by homing ot rTlultilineage 
donor leukocytes from the ol-gan graft to th8 recipient lymphoid tISsues where the 
Immune competent donol- and recipient leukocyte populations underwent reclprocai 
clonal activation (i,e. host-vErsus-graft (HVG) and graft-versus-host (GVH) reactions) 
(Figure 5) 
For organ engraftment, the two immune responses must be succeeded by z, significant 
degree of reciprocal clonal exhaustion-deletion (Figure 5). The long-term maintenance 
of this acutely-achieved state of variable deletional tolerance depends on persistence of 
the donor leukocytes (micro- or macrochimerism) whose survival IS'aided by a second 
mechanism of immune indifference,54,55 Both mechanisms of antigen-specific 
non reactivity (clonal exhaustion-deletion and immune ignorance) are regulated by 
migration and localiz.ation of the only mobile antigen of the organ, namely, the donor 
leukocytes.S4.S5 
Such organ-induced tolerance has been well documented in the absence of immuno-
suppression in a limited number of mouse, rat and pig models, most frequently involving, 
but not limited to, transplantation of the leukocyte rich liver (summarized in ref. 47), In 
most models, however, and clinically, an umbrella of immunosuppression is required_ 
Otherwise, one immunocyte population destroys the other before the tolerogenic 
Figure 5, Total number of pancreas transplants as reported by the International Pancreas Transplant 
Registry, as of August 200 I. Reproduced from Newsletter 13( I), 200 I, with permission from the 
International Pancreas Transplant Registry. 
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events can occur (Figure 5). The usual outcome is organ rejection, but graft-versus-host 
disease (GVHD) may be the dominant pathophysiology in a number of experimental 
models and clinically. The outcomes of rejection or GVHD can be forestalled or 
permanently prevented in many animal models by treating the organ recipiem after 
transplantation with a short course of a wide variety of immunosuppressive drugs, or 
sometimes with a single dose. 
Comparably conducive conditions for tolerance after human organ transplantation 
are predictably present only when tissues and organs are transplanted from HLA 
identical sibling donors. In addition, the short-term immunosuppl-ession used in 
experimental organ transplant models is contrary to the policy of heavy early 
immunosuppression (so-called 'induction therapy'), and to the commitment made at the 
outset to lifetime therapy. The early loss of allografts from immunological causes has 
been all but eliminated by intense immunosuppression, but not chronic rejection. 
Because immune activation and subsequent clonal exhaustion-deletion is the seminal 
mechanism by which variable organ-induced non-reactivity is achievedsl-sS, the obvious 
question is whether conventional heavy immunosuppression early after transplantation 
erodes the window of opportunity for tolerogenesis that is opened with immune 
activation a few hours after graft revascularization reaches a zenith in 1-3 weeks, and is 
largely closed by I or 2 months (Figure 5). We have addressed this issue recently, and 
have proposed two key therapeutic principles that must be observed if low-dose or 
no-dose immunosuppression is to be achieved in pancreas and other kinds of organ 
recipients. 
The first treatment principle, exemplified by conventional bone marrow 
transplantation to cytoablated (e.g. irradiated) recipients, is that host pre-treatment 
facilitates alloengraftment. Near total chimerism with antigen-specific tolerance can be 
regularly established with clinical bone marrow transplantation to the cytoablated 
recipient, using minimal post-transplant immunosuppression. The reason is that, with 
host cytoablation before arrival of the mobile donor leukocytes, the donor-specific 
clonal expansion of the bone marrow recipient response is small enough to be acutely 
deleted by the infused donor haematopoietic cells before these donor cells are 
rejected. Although this has been accomplished clinically under the well standardized 
circumstances of conventional bone marrow transplantation. the widespread use of 
combined bone marrow-organ transplantation to cytoablated recipients has been 
precluded by the many parameters involved. of which the most restrictive is the need 
for a histocompatible donor for avoidance of GVHD. 
The second key therapeutic principle is the avoidance of excessive and/or inappro-
priately timed (and therefore antitolerogenic) immunosuppression. The strong 
prophylactic immunosuppression conventionally used to inhibit the donor-specific 
T-cell response and avert rejection of the graft passenger leukocytes coincidentaily 
limits the extent of exhaustion-deletion and tolerogenesis, as has been demonstrated 
experimentally with prednisone, cyclosporine, tacrolimus and other agents. 
Variable violations of both therapeutic principles are inevitable with compromise 
strategies between the radically different regimens of conventional bone marrow and 
organ transplantation. However. scrupulous adherence to the first principle of recipient 
pre-treatment, but using non-myelotoxic agents for conditioning (e.g. anti lymphoid 
antibody preparations). and observance of the second principle of minimal post-
transplant immunosuppression, should improve clinical results. In addition, because the 
graft passenger leukocytes constitute, in essence, the eqUivalent of a bone man"ow 
infusion, it is rational to expect that the infusion of adjunct donor bone marrow cells will 
facilitate the clonal deletion induced by the comparable graft migratory leukocytes. In 
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the pastS" St, this desired effect of adjunct donor bone marrow probably has been 
sUDvened by over-immunosuppressions: 
Either- without, 01- mon, likely with, adjunct donor bone man-ow infUSion, It may be 
possible to achieve drug-free tolerance in recipients of pancreas or othel- organs, using 
a clinical protOcol that was developed In 1966 after demonstrating that ALG had a 
more w!erogenlc effect when It was given before, rather than after-, kidney and liver 
tl-ansplantatlon in dogs,18 Under similar management in humans, but armed with 
modern drugs including powerful anti lymphoid antibody agents, a markedly reduced 
need for early and marntenance immunosuppression (Including nearly complete 
elimination of prednisone) has been reported from several centres. In Cambridge 
(England), Caine et al58 have treated cadaver kidney recipients With a few perioperative 
doses of a humanized depleting anti-CD52 monoclonal antibody (T and B cell plus 
monocyte reactive), followed by low maintenance doses of cyclosporine alone. The 
results have been duplicated by Allen Kirk and associates in Bethesda by combining 
the antibody treatment with maintenance rapamycin. s9 Further suggesting that the 
therapy is not immunosuppressant-specific, but depends on the dose and timing of 
therapy, Kirk obtained similar results using a potent polyclonal ALG (ThymoglobulinR) 
and low-dose rapamycin S9 
A potential era 4 
The two therapeutic principles of recipient pre-treatment and minimal post-transplant 
immunosuppression were applied in Pittsburgh between July and November 200 I for 
four adult recipients of pancreas-only cadaveric allografts and for 10 kidney-pancreas 
recipients. Ten of the patients were also infused perioperatively with 5-9 x lOS 
unmodified bone marrow cells from the same donor. The patients were preconditioned 
with 3-5 mg(kg ThymoglobulinR IJnder the cover of I g intravenous methopredniso-
lone as prophylaxis against cytokine reactions, Treatment post-transplantation was with 
tacrolimus only with a trough target level of 10 ng/ml unless clinically significant 
rejection prompted the addition of a prednisone bolus(s), maintenance prednisone, or a 
short course of sirolimus. 
All 14 of the pancreases and the 10 co-transplanted kidneys have functioned well 
with follow-ups that are now 2 weeks to 6 months. The absence, or easy control, of 
both early and late rejection in this consecutive cadaveric series, using minimum 
immunosuppression relative to all previous experience in pancreas transplantation, has 
been remarkable. The value of this approach has been supported by similar results in a 
contemporaneous series of 31 recipients of cadaveric kidneys who had even less need 
for immunosuppression other than tacrolimus monotherapy, An attempt at complete 
weaning of immunosuppression is planned for patients under monotherapy whose 
allograft biopsy(ies) at 100 days shows no evidence of destructive immunity. Patients 
who have donor leukocyte chimerism demonstrable by flow cytometry in blood 
samples (i.e. macrochimerism) will be considered particularly good candidates for 
weaning. 
PANCREATIC ISLET TRANSPLANTATION 
The concept of removing islets from the whole pancreas for separate engraftment was 
advanced as early as 1902.60 Eighty years later it was demonstrated in animal 
models61 .62 and clinically63 that a high rate of success with islet transplantation can be 
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expected in the absence of an immune barrier (i.e. using autografts). In most of the 
autotransplant trials, the pancreas was removed surgically (e.g. for pancreatitis), 
purified islets were extracted from the specimen, and these were infused Into the 
patient's liver via the portal vein. Efforts to duplicate such results with allograft islets 
were not rewarded with success in experimental animals until the 19805, or in humans 
until 1990. 
In the first successful transplantation of islet allografts, five patients in Pittsburgh 
underwent upper abdominal exenteration (which included removal of the liver, 
stomach and whole pancreas), followed by liver transplantation.64 The patients were 
rendered free of exogenous insulin for up to 5 years by intraportal infusion of 
pancreatic islet allografts that had been prepared from the pancreas of the liver donor. 
However, when the same investigators attempted islet transplantation in nearly three 
dozen patients with juvenile diabetes, complete long-term insulin independence was 
not achieved in any case. 
Subsequently, several groups have documented metabolic normalization after the 
transplantation of islet allografts in patients with type I diabetes. Some 237 such 
attempts were reported to the International Islet Transplant Registry (IITR) between 
1990 and 1999, with insulin independence at I year in about 10%.65 Most recently, 
Shapiro et al reported successful metabolic correction in seven consecutive type I 
recipients of islets, most commonly requiring islets from more than one donor.66 
Immunosuppression was provided initially with an anti-interleukin-2 receptor 
antagonist (daclizumab). Continuous post-transplant treatment was with a steroid-free 
drug combination based on tacrolimus. Efforts to duplicate these results in several 
European and American centres have confirmed the feasibility of the islet procedure, but 
not its reliability. 
Consequently, in addition to pursuing these trials in multiple centres, efforts are 
being made to determine the precise conditions that lead to more consistently 
successfu I engraftment: 
I. Isolation of islets. This first step involves enzymatic digestion of the pancreas67, 
achieved by intraductal injection of a solution containing collagenase or a recently 
improved blend of enzymes (LiberaseR). The digestion is combined with mechanical 
disruption in a semi-automated digestion chamber developed by Ricordi et al 68 
After separation of the islets and discard of the acinar cells, islet clusters remain of 
variable size, each ranging from 50 to 500 ~lm in diameter. The implantable pellet of 
islets has a compacted volume of only 1-3 ml. It has been estimated that 
approximately 50% of the original islet mass has already been lost by this stage. Ways 
of obtaining a better yield are being sought. 
2. CharacterizatIOn of the islets. Many studies have focused on the effect of different 
culture media and supplements that would allow preservation of islet mass. In 
addition to making islet transplantation an elective procedure, this would allow time 
to assess in vitro the function and other qualities of the potential grafts.69 .70 
Cryopreservation also has been shown to be feasible
'
I.72, but these methods at 
present entail a further Significant loss of islets. 
3. Genetic modification. Isolated islets can be altered to acquire resistance to toxic :lnd 
other faCIOI'S that cause [I-cell damage, but the clinical value of these methods has 
!lot been establishedK~OTR 
4. OlfferentiatlOn ;Jf :'Jrecursor cells into insulin producing tissues. This promising I-esc;lrch 
has <jemonstrated the feasibility of directing undifferentiating pancreatic J.nd 
,'xtra-pancreJ.tic clssue toward a I)-cell phenotype. including Insulin secretlonK;-"-~··P 
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5. imp/amotion site. Once isolated from their physiological and anatomical environ-
ment. isle, cells rapid!;, undergo metabolic fail Lit"'" necl"Osis and eventual Iv 
apopcosis.7'!.8U The Influence of the various Implantation sites on these advers~ 
events. Including the Immune response elicited. IS not known. Intestinal mucosa, 
thymus. spleen. kidney capsule, peritoneum, testicle. subcutaneous tissue, liver and 
intra-cerebral space have been evaluated.81 - 86 The most common implantation site 
in clinical trials has been within the liver via intra-portal inlectionlO.87 Whethel" the 
liver is the optimal place fOI" engraftment has not been proved. 
6. Glucose counter-regulation. In contrast to whole-organ transplantation, the glucagon 
response to hypoglycaemla and other counter-regulatory mechanisms in recipients 
of well-functioning islet grafts appears to be impaired88.89 ; this may be related to the 
implantation site. 
Immunosuppression and alloengraftment 
As described under Pancreas Transplantation, the engraftment of all whole organs, 
including the pancreas, begins with acute chimerism-dependent induction of some 
level of deletional tolerance. The subsequent maintenance of the clonal exhaustion 
requires the persistence of small numbers of donor leukocytes (microchimerism) 
whose survival is facilitated by migration of donor leukocytes to 'protected' non-
lymphoid areas where the donor cells may be 'ignored' by the host immune system 
until they leak back to host lymphOid organs and perpetuate clonal exhaustion-
deletion.54.55 In such cases, immune ignorance of the cells in non-lymphoid locations is 
a secondary (or collaborative) mechanism for maintenance of clonal deletion, as 
described in detail elsewheres4.55 
In contrast to whole organs, small bits of endocrine tissue that fail to reach 
organized lymphoid collections may be unrecognized by the host immune system. In 
an early example of such immune ignorance, Stone, Owings and Gey90 reported in 
1934 that parathyroid tissue, which had been cultured for 2 weeks and transplanted 
into loose areolar subcutaneous tissue, functioned for prolonged periods in canine and 
human recipients. Long regarded as not credible, the findings of these authors are 
explained in retrospect by two features of the procedure. The first was the choice of a 
subcutaneous implantation site, which. like other privileged sites (e.g. hamster cheek 
pouch. brain), has limited lymphatic drainage. The second feature of this procedure 
became apparent with Lafferty'S demonstration that tissue culture comparable to that 
used four decades earlier in the parathyrOid experiments of Stone et al depletes 
endocrine tissue of passenger leukocytes that are capable of migrating to host 
lymphoid organs.91 
In principle. the use of highly bio-compatible materials used to encapsulate islet cells 
is an attempt to achieve immune indifference with a mechanical barrier.92.93 eowev~rI 
because islets have insufficient donor leukocyte antigen to induce deletion. it is 
possible that the islet engraftment may be achieved primarily by immune ignorance 
without encapsulation, resembling the 'Stone-Lafferty' graft. This could occur if the 
small numbers of mobile donor leukocytes contained in a bolus of islets made their 
way to host lymphoid organs and were 'all' destroyed. allowing the leukocyte-depleted 
islets in distant non-lymphoid locations to be ignored by the host for long periods, or 
permanently. From practical experience. and particularly that of the Edmonton group, 
it would appear that the immunosuppression most conducive for this chain of events 
may be the same as that fo~ whole-organ transplantation: i.e. recipient pre-treatment 
and minimal steroid-free post-transplant therapy. 
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XENOTRANSPLANTATION 
The prospect of providing either a whole pancreas or islets for the large number of 
diabetic patients that could benefit from transplantation is limited by the shortage of 
donors. At present more than one islet donor is required to accomplish glucose 
normalization and long-term maintenance may require further cell infusions. The 
solution may be the use of animal donors.94 Because human and porcine insulin have 
high amino acid sequence homology and have other metabolic similarities, including 
glucose homeostasis and regulation of insulin secretion, the pig may be a suitable 
source for islet cells or for the whole pancreas. A pilot study performed in Sweden has 
shown that fetal porcine islets can be implanted in humans, but these xenografts have 
had short functional activity because of rejection by predominantly innate immune 
mechan isms.95 
The best characterized target antigen on the cells of lower mammals (e.g. pig) is the 
surface carbohydrate epitope galactose rx(I-3)galactose, which is similar to substances 
found on numerous bacteria, protozoa and viruses. Efforts to create transgenic pigs 
that have this and other suspect genes replaced or knocked-out are underway.96,97 
Combined with cloning technology, they may allow the creation of 'humanized' 
animals for clinical use. 
Practice points 
• besides insulin. a definitive treatment for type I diabetes can be achieved only 
with whole-pancreas or islet-cell transplantation 
• long-term normalization of glycaemia is achieved by whole-pancreas transplants. 
limited by technical complications of the extensive surgery 
• islet transplantation is non-invasive; it is limited in its use by the need for multiple 
donors 
• immunosuppressive regimens are necessary in both types of transplant to limit 
the negative effects of recurrent autoimmunity and allorejection 
• immunosuppressants allow successful transplants in adults, but not in children 
Research agenda 
• tolerization protocols need to be implemented. Immunological preconditioning 
by anti-T cell antibodies (e.g. Tymoglobulin) and donor bone marrow 
administration could represent a possible approach for the induction of 
haematological chimerism of the recipient 
• alternative sources of insulin-producing ~ cells can be found among the stem cells 
present in the individual's tissues (e.g. endocrine pancreas, bone marrow, liver). 
These precursors should be immunologically recognized and then induced to 
proliferate and differentiate I 
• the limit in organ availability can also be overcome by generating animal donors I 
(e.g. pigs) with tissues immunologically more acceptable by the human recipient. I 
allowing xenotransplantation 
----------------------~-~ -----
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